StepStone Group Portfolio holdings
StepStone Group is a private markets firm that builds customized investment portfolios, monitors them and advises investors. Its business spans primary and secondary fund investments plus co-investments, across private equity, real estate, infrastructure, real assets and private debt. Its founders, Monte Brem and Thomas Keck, had earlier made private equity investments at Pacific Corporate Group, as president and managing director respectively. StepStone went public on the Nasdaq in September 2020. The firm serves institutional investors and sponsors worldwide.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Affirm
AFRM
|
+$1.08M |
| 2 |
Confluent
CFLT
|
+$479K |
| 3 |
Freshworks
FRSH
|
+$455K |
| 4 |
HashiCorp, Inc. Class A Common Stock
HCP
|
+$433K |
| 5 |
Agiliti Inc
AGTI
|
+$337K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Procore
PCOR
|
+$461K |
| 2 |
TaoWeave Inc
TWAV
|
+$404K |
| 3 |
Rocket Lab Corp
RKLB
|
+$327K |
| 4 |
NeueHealth
NEUE
|
+$40 |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 49.66% |
| 2 | Technology | 24.28% |
| 3 | Industrials | 13.97% |
| 4 | Healthcare | 7.88% |
| 5 | Communication Services | 3.5% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
DELISTED
Dun & Bradstreet
DNB
| $255M | 47.16% |
22,042,226
| – | – |
2021 Q4
6 quarters
|
|
2
DELISTED
WalkMe Ltd. Ordinary Shares
WKME
| $100M | 18.4% |
10,366,855
| – | – |
2021 Q3
7 quarters
|
|
|
3
Rocket Lab Corp
RKLB
$37.8B
| $73.2M | 13.54% |
12,202,096
-71,318
| -0.6% | -$327K |
2021 Q3
7 quarters
|
|
4
UiPath
PATH
$7.18B
| $29.9M | 5.53% |
1,805,596
+19,069
| +1% | +$306K |
2021 Q3
7 quarters
|
|
5
Roblox
RBLX
$37.5B
| $18.9M | 3.5% |
469,052
+2,386
| +0.5% | +$95.8K |
2021 Q3
7 quarters
|
|
6
DELISTED
HilleVax
HLVX
| $11.6M | 2.15% |
676,569
| – | – |
2022 Q2
4 quarters
|
|
7
Entrada Therapeutics
TRDA
$171M
| $11.5M | 2.13% |
761,277
| – | – |
2021 Q4
6 quarters
|
|
8
DELISTED
MoneyLion Inc.
ML
| $9.36M | 1.73% |
779,050
+1
| +0% | +$12 |
2021 Q3
7 quarters
|
|
|
9
DELISTED
NeueHealth
NEUE
| $6.42M | 1.19% |
525,249
-3
| -0% | -$40 |
2021 Q3
7 quarters
|
|
10
Phathom Pharmaceuticals
PHAT
$503M
| $6.04M | 1.12% |
422,085
| – | – |
2021 Q3
7 quarters
|
|
|
NGM
11
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
| $4.07M | 0.75% |
1,573,357
| – | – |
2021 Q3
7 quarters
|
|
12
DELISTED
Rover Group, Inc. Class A Common Stock
ROVR
| $3.16M | 0.58% |
643,394
| – | – |
2021 Q3
7 quarters
|
|
13
DELISTED
Doma Holdings, Inc.
DOMA
| $2.94M | 0.54% |
595,179
| – | – |
2021 Q3
7 quarters
|
|
14
Tenaya Therapeutics
TNYA
$90.8M
| $2.71M | 0.5% |
462,163
| – | – |
2021 Q3
7 quarters
|
|
15
DELISTED
Vacasa, Inc. Class A Common Stock
VCSA
| $2M | 0.37% |
147,261
| – | – |
2021 Q4
6 quarters
|
|
|
16
Affirm
AFRM
$25.3B
| $1.25M | 0.23% |
+81,445
| New | +$1.08M |
2023 Q2
0 quarters
|
|
|
17
Freshworks
FRSH
$3.92B
| $803K | 0.15% |
45,674
+30,282
| +197% | +$455K |
2023 Q1
1 quarter
|
|
|
18
DELISTED
Confluent
CFLT
| $691K | 0.13% |
19,558
+17,110
| +699% | +$479K |
2022 Q4
2 quarters
|
|
19
Grove Collaborative
GROV
$45.7M
| $673K | 0.12% |
380,383
+3,038
| +0.8% | +$6.68K |
2022 Q2
4 quarters
|
|
|
20
DELISTED
HashiCorp, Inc. Class A Common Stock
HCP
| $387K | 0.07% |
+14,767
| New | +$433K |
2023 Q2
0 quarters
|
|
|
21
DELISTED
Agiliti Inc
AGTI
| $332K | 0.06% |
+20,101
| New | +$337K |
2023 Q2
0 quarters
|
|
22
Mirum Pharmaceuticals
MIRM
$5.61B
| $108K | 0.02% |
+4,179
| New | +$111K |
2023 Q2
0 quarters
|
|
23
Progyny
PGNY
$2.18B
| $102K | 0.02% |
+2,597
| New | +$93.7K |
2023 Q2
0 quarters
|
|
|
AMRS
24
DELISTED
Amyris Inc.
AMRS
| $2.9K | ﹤0.01% |
2,816
| – | – |
2022 Q4
2 quarters
|
|
|
25
TaoWeave Inc
TWAV
$5.62M
| – | – |
-6,155
| Closed | -$404K | – |
|
Similar funds
StepStone Group's Q2 2023 Portfolio in Review
As of Q2 2023, StepStone Group held 26 positions worth $541M, up 0.49% from $538M the previous quarter. Its ten largest holdings account for 96% of the portfolio.
StepStone Group's Q2 2023 filing shows 5 new, 6 increased, 2 reduced and 2 closed positions. Its largest new stake was Affirm: 81,445 shares worth $1.25M. The largest sale was Procore, an estimated $461K.
By sector, the portfolio is most concentrated in Financials at 50% of assets, down from 51% a quarter earlier, followed by Technology and Industrials.
- StepStone Group's largest Q2 2023 buy was Affirm: 81,445 shares worth $1.25M.
- StepStone Group added most to Confluent in Q2 2023, an estimated $479K increase.
- StepStone Group's biggest Q2 2023 reduction was Rocket Lab Corp, cutting an estimated $327K.
- StepStone Group fully exited Procore in Q2 2023, selling an estimated $461K.
- StepStone Group's ten largest holdings make up 96% of its $541M portfolio in Q2 2023.
- StepStone Group opened 5 new positions and closed 2 in Q2 2023.
- StepStone Group's portfolio value rose 0.49% quarter-over-quarter to $541M.
Based on StepStone Group's 13F filing for Q2 2023, filed 14 Aug 2023.